Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases.
暂无分享,去创建一个
[1] M. Luster,et al. The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[2] R. Kloos,et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. , 2002, The Journal of clinical endocrinology and metabolism.
[3] S. Mandel,et al. Radioactive iodine and the salivary glands. , 2003, Thyroid : official journal of the American Thyroid Association.
[4] David D. Smith,et al. The Implication of Lymph Node Metastasis on Survival in Patients with Well-Differentiated Thyroid Cancer , 2005, The American surgeon.
[5] E. Baudin,et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. , 2005, The Journal of clinical endocrinology and metabolism.
[6] S. Mandel,et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. , 2012, Thyroid : official journal of the American Thyroid Association.
[7] V. Livolsi,et al. Papillary thyroid carcinoma tall cell variant. , 2008, Thyroid : official journal of the American Thyroid Association.
[8] Stephanie L. Lee,et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[9] E. Baudin,et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.
[10] R. Lloyd,et al. An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] V. Zaydfudim,et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. , 2008, Surgery.
[12] Stephanie L. Lee. Complications of radioactive iodine treatment of thyroid carcinoma. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[13] S. Larson,et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] J. Shah,et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.
[15] S. Larson,et al. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.
[16] S. Larson,et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. , 2013, The New England journal of medicine.